Serotonergic effects of clozapine and its metabolites in hippocampal HT22 cells

Psychiatry Research

Volumn 112, Issue 3, 2002, Pages 221-229

  Heiser, Philip ^a   Hausmann, Christiane ^a   Frey, Joachim ^a   Geller, Frank ^a   Becker, Ralf ^a   Wesemann, Wolfgang ^a   Krieg, Jürgen Christian ^a   Remschmidt, Helmut ^a   Vedder, Helmut ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

Clozapine; Clozapine metabolites; Clozapine N oxide; Hippocampus; Nor clozapine; Schizophrenia; Serotonin

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; CLOZAPINE; CLOZAPINE N OXIDE; DRUG METABOLITE; NORCLOZAPINE; SEROTONIN RECEPTOR; SEROTONIN TRANSPORTER;

ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; HIPPOCAMPUS; HUMAN; HUMAN CELL; IN VITRO STUDY; INCUBATION TIME; PRIORITY JOURNAL; RECEPTOR AFFINITY; RECEPTOR DENSITY; SEROTONIN UPTAKE; SEROTONINERGIC SYSTEM; VELOCITY;

ANTIPSYCHOTIC AGENTS; CARRIER PROTEINS; CELLS, CULTURED; CLOZAPINE; DOSE-RESPONSE RELATIONSHIP, DRUG; HIPPOCAMPUS; HUMANS; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; MONOAMINE OXIDASE; NERVE TISSUE PROTEINS; NEURONS; RECEPTORS, SEROTONIN; SEROTONIN; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS;

EID: 0037112353     PISSN: 01651781     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-1781(02)00239-1     Document Type: Article

References (43)

1. Abi-Dargham A., Laruelle M., Aghajanian G.K., Charney D., Krystal J. The role of serotonin in the pathophysiology and treatment of schizophrenia. Journal of Neuropsychiatry and Clinical Neurosciences. 9:1997;1-17.
2. Ase A.R., Amidiss F., Herbert C., Huang N., van Gelder N.M., Reader T.A. Effects of antipsychotic drugs on dopamine and serotonin contents and metabolites, dopamine and serotonin transporters, and serotonin1A receptors. Journal of Neural Transmission. 106:1999;75-105.
3. Bompart G., Copin N., Djouadi F., Bastin J., Ordener C., Parini A. Monoamine oxidase in developing rat renal cortex: effect of dexamethasone treatment. European Journal of Pharmacology. 415:2001;19-26.
4. Buckholtz N.S., Freedman D.X., Middaugh L.D. Daily LSD administration selectively decreases serotonin2 receptor binding in rat brain. European Journal of Pharmacology. 109:1985;421-425.
5. Buckland P.R., D'Souza U., Maher N.A., McGuffin P. The effects of antipsychotic drugs on the mRNA levels of serotonin 5-HT2A and 5-HT2C receptors. Molecular Brain Research. 48:1997;45-52.
6. Burnet P.W., Chen C.P., McGowan S., Franklin M., Harrison P.J. The effects of clozapine and haloperidol on serotonin-1A, 2A and -2C receptor gene expression and serotonin metabolism in the rat forebrain. Neuroscience. 73:1996a;531-540.
7. Burnet P.W., Eastwood S.L., Harrison P.J. 5-HT1A and 5-HT2A receptor mRNAs and binding site densities are differentially altered in schizophrenia. Neuropsychopharmacology. 15:1996b;442-455.
8. Crook J.M., Tomaskovic-Crook E., Copolov D.L., Dean B. Decreased muscarinic receptor binding in subjects with schizophrenia: a study of the human hippocampal formation. Biological Psychiatry. 48:2000;381-388.
9. Dean B., Hayes W., Opeskin K., Naylor L., Pavey G., Hill C., Keks N., Copolov D.L. Serotonin2 receptors and the serotonin transporter in the schizophrenic brain. Behavioral and Brain Research. 73:1996;169-175.
10. Elman I., Goldstein D.S., Eisenhofer G., Folio J., Malhotra A.K., Adler C.M., Pickar D., Breier A. Mechanism of peripheral noradrenergic stimulation by clozapine. Neuropsychopharmacology. 20:1999;29-34.
11. Gaintner J.R., Jackson D.P., Maynert E.W. The action of thrombin on platelet 5-hydroxytryptamine. Bulletin of the Johns Hopkins Hospital. 111:1962;185-197.
12. Gerardy J., Dresse A. Regional action of brofaromine on rat brain MAO-A and MAO-B. Progress in Neuro-Psychopharmacology and Biological Psychiatry. 22:1998;1141-1155.
13. Grace A.A. Gating of information flow within the limbic system and the pathophysiology of schizophrenia. Brain Research Reviews. 31:2000;330-341.
14. Heiser P., Dickhaus B., Opper C., Schreiber W., Clement H.W., Hasse C., Henning J., Krieg J.C., Wesemann W. Platelet serotonin and interleukin-1β after sleep deprivation and recovery sleep in humans. Journal of Neural Transmission. 104:1997;1049-1058.
15. Hranilovic D., Schwab S.G., Jernej B., Knapp M., Lerer B., Albus M., Rietschel M., Kanyas K., Borrmann M., Lichtermann D., Maier W., Wildenauer D.B. Serotonin transporter gene and schizophrenia: evidence for association/linkage disequilibrium in families with affected siblings. Molecular Psychiatry. 5:2000;91-95.
16. 3H]imipramine localization and relationship to serotonin transporter. Journal of Pharmacology and Experimental Therapeutics. 252:1990;410-418.
17. Ichikawa J., Kuroki T., Dai J., Meltzer H.Y. Effect of antipsychotic drugs on extracellular serotonin levels in rat medial prefrontal cortex and nucleus accumbens. European Journal of Pharmacology. 19:1998;163-171.
18. Joseph M.H., Baker H.F., Crow A.J., Riley G.J., Risby D. Brain tryptophan metabolism in schizophrenia: a post-mortem study of metabolites on the serotonin and kynurenine pathways in schizophrenia and control subjects. Psychopharmacology. 62:1979;279-285.
19. Joyce J.N. The dopamine hypothesis of schizophrenia: limbic interactions with serotonin and norepinephrine. Psychopharmacology. 112:1993;16-34.
20. Joyce J.N., Shane A., Lexow N., Winokur A., Casanova M.F., Kleinman J.E. Serotonin uptake sites and serotonin receptors are altered in the limbic system of schizophrenics. Neuropsychopharmacology. 8:1993;315-336.
21. Kuperberg G., Heckers S. Schizophrenia and cognitive function. Current Opinion in Neurobiology. 10:2000;205-210.
22. Lakshmana M.K., Rao B.S., Dhingra N.K., Ravikumar R., Govindaiah S., Meti B.L., Raju T.R. Role of monoamine oxidase type A and B on the dopamine metabolism in discrete regions of the primate brain. Neurochemical Research. 23:1998;1031-1037.
23. Matsubara S., Meltzer H.Y. Effect of typical and atypical antipsychotic drugs on 5-HT2 receptor density in rat cerebral cortex. Life Sciences. 45:1989;1397-1406.
24. Meltzer H.Y. An overview of the mechanism of action of clozapine. Journal of Clinical Psychiatry. 55 (Suppl. B):1994;47-52.
25. Meltzer H.Y., Bastani B., Ramirez L., Matsubara S. Clozapine: new research on efficacy and mechanism of action. European Archives of Psychiatry and Clinical Neuroscience. 238:1989;332-339.
26. Meszaros Z., Borcsiczky D., Mate M., Tarcali J., Tekes K., Magyar K. MAO inhibitory side effects of neuroleptics and platelet serotonin content in schizophrenic patients. Journal of Neural Transmission (Suppl.). 52:1998;79-85.
27. Morimoto B.H., Koshland D.E. Induction and expression of long- and short-term neurosecretory potentiation in a neural cell line. Neuron. 5:1990;875-880.
28. Nadel L., Samsonovich A., Ryan L., Moscovitch M. Multiple trace theory of human memory: computational, neuroimaging, and neuropsychological results. Hippocampus. 10:2000;352-368.
29. 3H]paroxetine. Journal of Neural Transmission Genetic Section. 103:1996;749-757.
30. Ohuoha D.C., Hyde T.M., Kleinmann J.E. The role of serotonin in schizophrenia: an overview of the nomenclature, distribution and alterations of serotonin receptors in the central nervous system. Psychopharmacology (Berlin). 112:1993;5-15.
31. Peroutka S.J. Serotonin receptor variants in disease: new therapeutic opportunities? Annals of the New York Academy of Sciences. 861:1998;16-25.
32. Razi K., Greene K.P., Sakuma M., Ge S., Kushner M., DeLisi L.E. Reduction of the parahippocampal gyrus and the hippocampus in patients with chronic schizophrenia. British Journal of Psychiatry. 174:1999;512-519.
33. Remschmidt H., Schulz E., Martin M. An open trial of clozapine in thirty-six adolescents with schizophrenia. Journal of Child and Adolescent Psychopharmacology. 4:1994;31-41.
34. 3H-paroxetine in human brain. Journal of Neural Transmission. 104:1997;89-96.
35. 3H-imipramine binding: influences of protein concentration of varying proportions of cytosol or intact platelets and displacing agents used. Biological Psychiatry. 38:1995;464-470.
36. Sanders-Bush E. The serotonin receptors. Humana, Totowa. 1998;3-4.
37. Scarr E., Copolov D.L., Dean B. A proposed pathological model in the hippocampus of subjects with schizophrenia. Clinical and Experimental Pharmacology and Physiology. 28:2001;70-73.
38. Schreiber W., Opper C., Dickhaus B., Heiser P., Wesemann W., Krieg J.C. Alterations of blood platelet MAO-B activity and LSD-binding in humans after sleep deprivation and recovery sleep. Journal of Psychiatric Research. 31:1997;323-331.
39. Schulz E., Fleischhaker C., Remschmidt H. Determination of clozapine and its major metabolites in serum samples of adolescent schizophrenic patients by high performance liquid chromatography. Data from a prospective clinical trial. Pharmacopsychiatry. 28:1995;20-25.
40. Schulz E., Fleischhaker C., Clement H.W., Remschmidt H. Blood biogenic amines during clozapine treatment of early-onset schizophrenia. Journal of Neural Transmission. 104:1997;1077-1089.
41. Thomas D.R., Nelson D.R., Johnson A.M. Biochemical effects of the antidepressant paroxetine, a specific 5-hydroxytryptamine uptake inhibitor. Psychopharmacology (Berlin). 93:1987;193-200.
42. Willins D.L., Berry S.A., Alsayegh L., Backstrom J.R., Sanders-Bush E., Friedman L., Roth B.L. Clozapine and other 5-hydroxytryptamine-2A receptor antagonists alter the subcellar distribution of 5-hydroxytryptamine-2A receptors in vitro and in vivo. Neuroscience. 91:1999;599-606.
43. Winblåd B., Bucht G., Gottfries C.G., Ross B.E. Monoamines and monoamine metabolites in brains from demented schizophrenics. Acta Psychiatrica Scandinavica. 60:1979;17-28.